You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 19, 2024

Claims for Patent: 9,126,977


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,126,977
Title:Methods for treating antipsychotic-induced weight gain
Abstract: The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
Inventor(s): Deaver; Daniel (Franklin, MA), Todtenkopf; Mark (Franklin, MA)
Assignee: Alkermes Pharma Ireland Limited (Dublin, IE)
Application Number:14/297,171
Patent Claims: 1. A method of reducing antipsychotic induced weight gain comprising administering to the patient in need of treatment an effective amount of a compound of Formula I; ##STR00022## wherein, A is chosen from --C(.dbd.O)NH.sub.2 and --C(.dbd.S)NH.sub.2; R.sup.1 and R.sup.2 are both hydrogen or taken together R.sup.1 and R.sup.2 are .dbd.O; R.sup.3 is chosen from hydrogen, alkyl, alkenyl, aryl, heterocyclyl and hydroxyalkyl; R.sup.4 is chosen from hydrogen, hydroxy, amino, alkoxy, C.sub.1-C.sub.20 alkyl and C.sub.1-C.sub.20 alkyl substituted with hydroxy or carbonyl; R.sup.5 is selected from hydrogen, hydroxyl, alkoxy and alkyl; R.sup.6 is chosen from hydrogen, hydroxy, alkoxy and --NR.sup.10R.sup.11; or together, R.sup.5 and R.sup.6 form a carbonyl or a vinyl substituent; R.sup.10 and R.sup.11 are chosen independently from hydrogen and alkyl and aliphatic; and, represents a single or double bond.

2. The method of claim 1, wherein said compound of Formula I is selected from a compound of Formula II: ##STR00023## wherein, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are as defined above.

3. The method according to claim 1, wherein said compound of Formula I is selected from Table A: TABLE-US-00002 TABLE A 1 ##STR00024## 2 ##STR00025## 3 ##STR00026## 4 ##STR00027## 5 ##STR00028## 6 ##STR00029## 7 ##STR00030## 8 ##STR00031## 9 ##STR00032## 10 ##STR00033## 11 ##STR00034## 12 ##STR00035## 13 ##STR00036## 14 ##STR00037## 15 ##STR00038## 16 ##STR00039## 17 ##STR00040## 18 ##STR00041##

4. The method according to claim 1, wherein the weight gain is induced by administration of an atypical antipsychotic.

5. The method according to claim 1, wherein said compound is Compound 1: ##STR00042##

6. The method of claim 4, wherein the atypical antipsychotic is selected from the group consisting of olanzapine, clozapine, risperidone, quetiapine, aripiprazole, ziprasidone, and pharmaceutically acceptable salts thereof.

7. The method of claim 6, wherein the atypical antipsychotic is used in the treatment of schizophrenia, bipolar disorder, dementia, acute mania, major depression and psychotic agitation.

8. A method of reducing Ghrelin level in the gastrointestinal tract comprising the step of administering a compound of Formula I to a patient in need thereof.

9. The method according to claim 8, wherein said compound of Formula I is Compound 1.

10. A composition comprising an atypical antipsychotic and a compound of Formula I; ##STR00043## wherein, A is chosen from --C(.dbd.O)NH.sub.2 and --C(.dbd.S)NH.sub.2; R.sup.1 and R.sup.2 are both hydrogen or taken together R.sup.1 and R.sup.2 are .dbd.O; R.sup.3 is chosen from hydrogen, alkyl, alkenyl, aryl, heterocyclyl and hydroxyalkyl; R.sup.4 is chosen from hydrogen, hydroxy, amino, alkoxy, C.sub.1-C.sub.20 alkyl and C.sub.1-C.sub.20 alkyl substituted with hydroxy or carbonyl; R.sup.5 is selected from hydrogen, hydroxyl, alkoxy and alkyl; R.sup.6 is chosen from hydrogen, hydroxy, alkoxy and --NR.sup.10R.sup.11; or together, R.sup.5 and R.sup.6 form a carbonyl or a vinyl substituent; R.sup.10 and R.sup.11 are chosen independently from hydrogen and alkyl and aliphatic; and represents a single or double bond.

11. The composition of claim 10, wherein said atypical antipsychotic is selected from olanzapine, clozapine, risperidone, quetiapine, aripiprazole, and ziprasidone.

12. The composition of claim 10, wherein said compound of Formula I is selected from Table A: TABLE-US-00003 TABLE A 1 ##STR00044## 2 ##STR00045## 3 ##STR00046## 4 ##STR00047## 5 ##STR00048## 6 ##STR00049## 7 ##STR00050## 8 ##STR00051## 9 ##STR00052## 10 ##STR00053## 11 ##STR00054## 12 ##STR00055## 13 ##STR00056## 14 ##STR00057## 15 ##STR00058## 16 ##STR00059## 17 ##STR00060## 18 ##STR00061##

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.